Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
Status:
Completed
Trial end date:
2019-07-20
Target enrollment:
Participant gender:
Summary
CORALLEEN is a two-arm, randomized, multicentric study in postmenopausal women with primary
HR+/HER2 negative Luminal B breast cancer that will explore if the combination of ribociclib
with letrozole offers clinical benefit at least comparable to that of standard chemotherapy.